Gut microbiota participates and remodels host metabolism: from treating patients to treating their gut flora
Editorial published in World Journal of Gastroenterology (2024)
Abstract
In this editorial, we comment on Liu et al's article published in the recent issue of the World Journal of Gastroenterology. Biochemically and pathologically, Liu et al proved that the urate-lowering activity of leech total protein (LTP) was mainly attributed to the rectification of gut microbiota. Specifically, we noticed the change in Bacteroides and Akkermansia after LTP administration. Both bacteria have been reported to alleviate metabolic dysfunction-associated steatohepatitis and other chronic metabolic diseases. LTP was administrated through intragastric manners. Most possibly, LTP would be digested by the gut microbiota further. The anti-hyperuricemia effects should, to the most possible extent, be exerted by the peptides or their secondary metabolic products. Human gut microbiota communicates with other organs through metabolites generated by the microbes or co-metabolized with the host. Whether the anti-hyperuricemia effect could be partially ascribed to the microbiota metabolites also deserves to be discussed. Although metabolomics analysis was performed for serum samples, fecal metabolomics was highly advocated which could facilitate exact mechanism explanation. This study implied that gut microbiota contains many unexplored targets with different therapeutic potentials. It is foreseeable that utilizing these targets can avoid the impairment or side effects of directly using human targets to some extent.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Editorial commentary on leech total-protein modulation of gut microbiota for hyperuricemia treatment — explores microbiota-mediated mechanisms of leech-derived therapeutic peptides.
Por qué esto importa para la hirudoterapia
Este editorial discute los hallazgos de Liu et al. de que la proteína total de la sanguijuela (LTP, por sus siglas en inglés) ejerce actividad reductora de urato principalmente a través de la rectificación de la microbiota intestinal, con cambios específicos observados en las poblaciones de Bacteroides y Akkermansia tras la administración intragástrica. El editorial sugiere que los efectos anti-hiperuricémicos pueden ser ejercidos por péptidos o productos metabólicos secundarios, y plantea la cuestión de si los metabolitos de la microbiota contribuyen. La relevancia para el secretoma de la sanguijuela radica en que se está explorando una preparación proteica derivada de la sanguijuela para aplicaciones en enfermedades metabólicas mediante la modulación de la microbiota intestinal. La principal limitación es que se trata de un editorial que comenta la investigación de otro grupo, sin presentar datos experimentales originales, y el resumen no aborda las aplicaciones clásicas de la hirudoterapia.
Citación
Gut microbiota participates and remodels host metabolism: from treating patients to treating their gut flora.
Han S et al. · World journal of gastroenterology, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026